BioCentury | Aug 29, 2020
Emerging Company Profile

Arctic Vision sets sights on China’s innovation gap in ophthalmology

...and Taiwan. The therapy, which the company is developing for uveitis as ARVN001, is a triamcinolone acetonide...
...millionInvestors: Nan Fung Life Sciences, Pivotal China, Morningside VenturesCEO: Eddy WuPatents: Undisclosed Elizabeth S. Eaton MicroPine Xipere, Zuprata, triamcinolone acetonide...
BioCentury | Jul 15, 2020
Finance

Pandemic-generated demand behind strong sales of Flexion’s osteoarthritic drug

...Tuesday, Flexion Therapeutics Inc. (NASDAQ:FLXN) closed up 12% to $13.12 after reporting that Zilretta sustained-release triamcinolone acetonide...
...Consensus figures provided by FactSet. Lauren Martz, Senior Editor Zilretta (Brand), FX006 (Compound #), Sustained-release triamcinolone acetonide (Generic), triamcinolone acetonide...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...it get to “go/no-go” decisions faster. BioCentury Staff CK-274 (CK-3773274) Zilretta (Brand), FX006 (Compound #), Sustained-release triamcinolone acetonide (Generic), triamcinolone acetonide...
BioCentury | Apr 2, 2020
Product Development

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

...Ltd. and Jiangsu Tainuo Pharmaceutical Co. Ltd. local rights to develop and commercialize Zilretta sustained-release triamcinolone acetonide...
BioCentury | Feb 22, 2019
Clinical News

FDA issues handful of new PDUFA dates

...Biomedical Inc. (NASDAQ:CLSD) announced an Oct. 19 PDUFA date for Xipere Zuprata, a microinjection of triamcinolone acetonide...
BioCentury | Dec 8, 2018
Regulation

Path to opioid-free pain relief

...to collect data on opioid-sparing activity in trials of its osteoarthritis knee pain product Zilretta triamcinolone acetonide...
BioCentury | Nov 9, 2018
Clinical News

Clearside discontinues combo therapy for retinal vein occlusion

...for Xipere to treat macular edema associated with non-infectious uveitis. Xipere is a suspension of triamcinolone acetonide...
...Ga. Product: Xipere (formerly CLS-TA) Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR) Description: Suspension of triamcinolone acetonide...
BioCentury | Sep 12, 2018
Company News

Management tracks: Clearside, ImCheck

...candidate Zuprata (CLS-TA) to treat macular edema by year end. Zuprata is a suspension of triamcinolone acetonide...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...PDUFA date 7/10/18 Celgene Corp. (NASDAQ:CELG) Fedratinib Myelofibrosis Submit NDA 2H18 Clearside Biomedical Inc. (NASDAQ:CLSD) Triamcinolone acetonide...
...associated with retinal vein occlusion (RVO) Ph III SAPPHIRE data 4Q18 Clearside Biomedical Inc. (NASDAQ:CLSD) Triamcinolone acetonide...
BioCentury | Jun 1, 2018
Clinical News

Clearside reports Phase II DME data for CLS-TA

...could receive Eylea at months four and five as needed. CLS-TA is a suspension of triamcinolone acetonide...
...NASDAQ:CLSD), Alpharetta, Ga. Product: CLS-TA Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR) Description: Suspension of triamcinolone acetonide...
Items per page:
1 - 10 of 125